A detailed history of Criteria Caixa, S.A.U. transactions in Abb Vie Inc. stock. As of the latest transaction made, Criteria Caixa, S.A.U. holds 542,984 shares of ABBV stock, worth $114 Million. This represents 13.77% of its overall portfolio holdings.

Number of Shares
542,984
Holding current value
$114 Million
% of portfolio
13.77%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Feb 14, 2025

BUY
$164.99 - $203.87 $89.6 Million - $111 Million
542,984 New
542,984 $96.5 Billion
Q4 2023

Mar 18, 2025

BUY
$137.6 - $154.97 $3.19 Million - $3.59 Million
23,181 Added 4.46%
542,984 $84.1 Billion
Q3 2023

Mar 18, 2025

BUY
$133.59 - $154.65 $133,590 - $154,650
1,000 Added 0.19%
519,803 $77.5 Billion
Q2 2023

Mar 18, 2025

BUY
$132.51 - $164.9 $1.02 Million - $1.27 Million
7,688 Added 1.5%
518,803 $69.9 Billion
Q1 2022

Mar 18, 2025

SELL
$131.98 - $163.75 $2 Million - $2.48 Million
-15,122 Reduced 2.87%
511,115 $82.9 Billion
Q4 2021

Mar 18, 2025

BUY
$107.43 - $135.93 $753,406 - $953,277
7,013 Added 1.35%
526,237 $71.3 Billion
Q3 2021

Mar 18, 2025

BUY
$106.4 - $120.78 $292,600 - $332,145
2,750 Added 0.53%
519,224 $56 Billion
Q2 2021

Mar 18, 2025

BUY
$105.21 - $117.21 $641,781 - $714,981
6,100 Added 1.2%
516,474 $58.2 Billion
Q1 2021

Mar 18, 2025

BUY
$102.3 - $112.62 $4.53 Million - $4.98 Million
44,263 Added 9.5%
510,374 $55.2 Billion
Q4 2020

Mar 18, 2025

BUY
$80.49 - $108.67 $92,563 - $124,970
1,150 Added 0.25%
466,111 $49.9 Billion
Q4 2019

Mar 18, 2025

SELL
$72.13 - $90.25 $5.63 Million - $7.04 Million
-78,023 Reduced 14.37%
464,961 $41.2 Billion

Others Institutions Holding ABBV

About AbbVie Inc.


  • Ticker ABBV
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,768,099,968
  • Market Cap $370B
  • Description
  • AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...
More about ABBV
Track This Portfolio

Track Criteria Caixa, S.A.U. Portfolio

Follow Criteria Caixa, S.A.U. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Criteria Caixa, S.A.U., based on Form 13F filings with the SEC.

News

Stay updated on Criteria Caixa, S.A.U. with notifications on news.